Search Results
MAHOGANY: margetuximab in gastric cancer
Updates from the MAHOGANY study in gastric cancer
MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA
Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric:GEJ Cancer
Margetuximab Along With Retifanlimab in High Expressing HER2+ Gastric Cancer
Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer
Margetuximab for the Treatment of HER2+ Breast Cancer
Dr. Rugo on the Impact of Margetuximab Based on CD16A Fc Receptors in HER2+ Breast Cancer
Dr. Blackwell Discusses Margetuximab for HER2+ Breast Cancer
32 First Line Therapy for HER2+ GEA
Updates in treatments for HER2-positive GEA
Dr. Crew on Updated Data With Margetuximab in HER2+ Breast Cancer
